BioAdaptives Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $5.5K | $10.4K | $4.6K | $3.2K | $0 | $0 | $0 |
| Cost of Revenue | $748 | $1.4K | $2.8K | $781 | $2.2K | $0 | $0 | $0 |
| Gross Profit | $4.2K | $4.1K | $7.6K | $3.9K | $1.1K | $0 | $0 | $0 |
| Gross Margin | 85.0% | 74.6% | 72.7% | 83.1% | 33.0% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $177.7K | $181.1K | $228.3K | $251.0K | $197.9K | $143.4K | $258.6K | $40.4K |
| Operating Income | $-197.2K | $-198.2K | $-248.1K | $-265.7K | $-279.2K | $-249.1K | $-337.3K | $-121.9K |
| Operating Margin | -3,953.0% | -3,594.8% | -2,379.6% | -5,735.9% | -8,674.1% | — | — | — |
| Interest Expense | — | $87.8K | $37.4K | $14.2K | $9.6K | $9.6K | $9.7K | $9.7K |
| Pretax Income | $150.1K | $-111.1K | $-823.3K | $-379.5K | $-157.9K | $-197.1K | — | $-37.6K |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $150.1K | $-111.1K | $-823.3K | $-379.5K | $-157.9K | $-197.1K | $-371.8K | $-37.6K |
| Net Margin | 3,009.0% | -2,014.6% | -7,896.3% | -8,193.0% | -4,905.7% | — | — | — |
| EPS (Basic) | $0.01 | — | — | — | $-0.02 | — | — | $0.00 |
| EPS (Diluted) | $0.00 | $-0.01 | $-0.07 | $-0.04 | $-0.02 | $-0.02 | $-0.13 | $0.00 |
| Shares Outstanding (Basic) | 14.2M | — | — | — | 9.5M | — | — | 895.8M |
| Shares Outstanding (Diluted) | 281.2M | 12.0M | 10.1M | 10.2M | 9.5M | 9.0M | 8.2M | 8.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |